Personalis, Inc.
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tiā¦ read more
Healthcare
Diagnostics & Research
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.93
Price-3.55%
-$0.26
1Y
Price
Market Cap
$615.380m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-101.6%
EBITDA Margin-116.6%
Net Profit Margin-76.9%
Free Cash Flow MarginRevenue
$80.317m
-5.1%
1y CAGR+7.7%
3y CAGR-0.2%
5y CAGREarnings
-$91.320m
-12.3%
1y CAGR+5.7%
3y CAGR-14.2%
5y CAGREPS
-$1.28
+6.6%
1y CAGR+18.3%
3y CAGR-2.9%
5y CAGRBook Value
$190.829m
$258.680m
Assets$67.851m
Liabilities$42.438m
DebtDebt to Assets
16.4%
-0.5x
Debt to EBITDAFree Cash Flow
-$49.184m
-5.2%
1y CAGR+23.1%
3y CAGR+5.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company